GPC3 and hepatocellular carcinoma: Two sequential phase 1 clinical trials (ClinicalTrials.gov, NCT02395250, ClinicalTrials.gov, NCT03146234) have observed antitumor activity of CAR‐GPC3 T cells in HCC patients and demonstrate that the treatment is feasible with preliminary safety.295